Factors related to hospitalization for heart failure (HF) following coronary artery bypass grafting (CABG) surgery were studied.
Introduction
More than 300 000 coronary artery bypass grafting (CABG) operations are performed annually in the USA. 1 Coronary revascularization by surgical techniques is performed in patients with a wide spectrum of left ventricular ejection fractions (EFs), and CABG is the preferred treatment for patients with three-vessel disease and depressed EF. 2 -5 Although the value of revascularization with heart failure (HF) is still under debate, the improvement in survival of CABG patients with left ventricular dysfunction enlarged the cohort of patients who might be re-hospitalized, due to HF after surgery. 6, 7 Several studies have reported the association between left ventricular function and operative mortality. 8, 9 However, no large studies have focused on trends and incidence of HF after CABG surgery. We examined trends and factors related to HF admissions after CABG using 10-year data from a statewide database.
Methods

Study population
We used data from the New Jersey Open Heart Surgery Registry, a mandatory reporting system that contains all cardiac surgeries performed in the state since 1994, and the Myocardial Infarction Data Acquisition System (MIDAS), 10 an ongoing statewide administrative database that contains all hospital discharges with a diagnosis of cardiovascular disease (CVD). Hospital admissions for HF after open heart surgery were identified by linkage of these two databases, and within each database longitudinally using LINK-KING, a public domain record linkage software (www.the-link-king.com). 11 This allows us to examine episodes of care at the patient level longitudinally. Vital status was ascertained by linking to New Jersey death registration files. MIDAS includes all hospitalizations for HF in the state since all non-federal hospitals must report their admissions to the state from where the data are obtained. Entering the data is the responsibility of the individual hospitals. State and federal authorities audit the completeness and accuracy of the data. This database was previously audited using a random sample of charts to verify the accuracy of the information. 12 The Institutional Review Boards of the New Jersey normal EF( ≥ 50%) constitutes the comparison group; patients with reduced EF were further grouped into three common clinical categories, i.e. moderately reduced (35-49%), markedly reduced (25 -34%), and severely reduced EF (,25%).
13,14
Outcome measures
Both hospitalization and mortality data were available up to 31 December 2009. Hospital admission due to HF up to 2 years after CABG surgery was evaluated as the primary outcome. HF admission was defined by the presence of an International Classification of Diseases, 9th Revision, Clinical Modification (ICD 9-CM) code of 428, a code that includes all HF admissions regardless of systolic or diastolic dysfunction, in one of the nine diagnostic fields. All-cause mortality during the index hospitalization (in-hospital), and at 1-year and 2-year follow-up from the CABG surgery date were compared among the four EF groups.
Statistical analysis
Patient characteristics were compared among the four EF groups. x 2 test and analysis of variance (ANOVA) test were used as appropriate for univariate comparisons; significances of tests were two-sided. Trends of rates were analysed using log-linear regression models.
Multivariate logistic regression models were used to examine risk factors associated with in-hospital mortality overall and for each EF group. Proportional hazards models were used to identify factors related to HF admission after CABG and mortality at 1-and 2-year follow-up. Confounders including patient demographics, co-existing conditions, and interventional procedures, and with a P , 0.25 in univariate analysis, were entered into the multivariate models. SAS 9.2 (SAS Institute, Cary, NC, USA) was used for the analysis.
Results
Patient characteristics
Baseline characteristics are shown in Table 1 . Of the 65 377 CABG patients, 5.1% had an EF ,25%, 9.4% an EF between 25% and 34%, 30.6% an EF between 35% and 49%, and 54.9% an EF ≥ 50%. Patients with a low EF (,50%) were less likely to be female or hypertensive, and were more likely to have history of smoking, diabetes, chronic renal failure, and chronic lung disease, and had an emergent or urgent surgery. Also, these patients had more left main disease, and a history of recent myocardial infarction (MI), HF, and cardiogenic shock. Pre-operative use of an ACE inhibitor and i.v. nitrates was more frequent in patients with low EF (,50%), while beta-blockers were used less in patients with EF ,25%. IABP was used in 7% of CABG patients, ranging from 22% use in the EF ,25% group to 4% in normal EF patients.
From 1998 to 2007, the average EF of CABG patients had changed from 46% (+ 13%) to 48% (+ 12%) (P for trend ¼ Figure 2 In-hospital (a) and 2-year mortality (b) trends by ejection fraction among patients undergoing coronary artery bypass grafting surgery in New Jersey, 1998-2007. Note: the two lowest and two highest ejection fraction groups were combined because of low event rates.
HF trends after CABG 0.0005). The overall improvement in EF was mainly due to a decline in the proportion of patients with an EF between 25% and 49% (from 46% to 36%, P for trend ,0.0001), while the proportion of patients with EF ,25% remained little changed at 5% (P ¼ 0.1) (Figure 1 ).
All-cause mortality rates after coronary artery bypass grafting
The overall mortality was 1.8% at in-hospital, 5.1% at 1 year, and 7.2% at 2 years after CABG ( Table 2) . In-hospital mortality rates were 4.3, 3.5, 2.0, and 1.1% for groups with EF ,25%, 25 -34%, 35 -49%, and ≥ 50%, respectively. A similar pattern was also observed for 1-and 2-year mortality. We observed a decreasing trend in both in-hospital and 2-year mortality among those with an EF ,35% (P for trend ¼ 0.005) but no change over time among patients with an EF .35% (Figure 2 ).
Ejection fraction was strongly associated with mortality both at discharge and up to 2 years after surgery ( Table 3) . Multivariate analysis adjusting for demographics and co-morbidities indicated that patients with a low EF had a 1.5 -2.7 times higher risk of in-hospital and 2-year mortality compared with the group with EF ≥ 50%. Other factors associated with increased mortality were: age, female gender, Black race, current smoker, diabetes, chronic renal disease, acute MI (AMI), and left main disease. Preoperative use of beta-blockers or ACE inhibitors had no impact on either in-hospital or 2-year mortality.
Impact of pre-operative beta-blocker and angiotensin-converting enzyme inhibitor use on heart failure admission after coronary artery bypass grafting After CABG, the overall admission rate for HF was 15.7% at 1 year and 18.8% at 2 years ( rates of HF admission by multivariate analysis ( Figure 3) were: EF, age, female gender, Black or Hispanic racial groups, current smoker, diabetes, and chronic renal disease. Pre-operative use of a beta-blocker or aspirin significantly decreased the likelihood of HF admission by 14.6%, whereas the use of ACE inhibitors increased the likelihood of HF admission by 15.1%. The benefit of beta-blockers on HF admission after CABG was seen in patients of all EF groups, but was most pronounced among patients with the lowest EF. ACE inhibitor use was associated with higher HF admissions, especially among EF ≥ 35% patients ( Table 4) . When we examined the medication use over time, there was an overall increase in the use of beta-blockers and ACE inhibitors from 1998 to 2007. The increase in the use of beta-blockers was more pronounced in patients with severely reduced EF (from 49% to 83%) compared with an increase from 62% to 79% among patients with EF ≥ 50%. In contrast, the increase in the use of ACE inhibitors was less pronounced in patients with EF ,25% (from 51% to 57%) compared with the increase among patients with normal EF (from 23% to 45%). Despite the increasing use of beta-blockers, the HF admission rate increased significantly during the study period among patients with low EFs; from 35% to 42% in those with severely reduced EF (,25%), and from 28% to 36% in those with markedly reduced EF (25 -34%) (P , 0.0001; Figure 4 ).
Discussion
We studied 65 377 patients undergoing CABG in New Jersey between 1998 and 2007 and their HF admission rates up to 2 years after surgery. We observed that 19% of patients were admitted with HF within 2 years after CABG. As expected, HF admission rates were high after CABG in patients with low EF, but even among patients with normal EF, the HF admission rate within 2 years was notably high (13%).
The overall mortality of patients undergoing CABG was low, with minimal change during the 10-year study period. We identified EF as the strongest predictor for short-and long-term mortality, with about a twice higher risk of death in patients with low EF in the adjusted models. In our study, patients with low EF had much lower mortality than that reported in the decade 1990-2000, 9, 15 and in agreement with the rates reported by Argerizano et al. in New York Heart Association (NYHA) class IV HF patients. 5 Although beta-blockade has a class I recommendation for patients with HF, there has been concern in the surgical community about the pre-operative use of beta-blockers in patients with EF ,30%. 16 In our study, pre-operative beta-blocker use had no significant impact on mortality, even among patients with low EF. Studies examining the trends of mortality among CABG patients found a 20% relative decline in in-hospital mortality in the last Figure 3 Risk factors associated with heart failure admission at 2 years after coronary artery bypass grafting (CABG) surgery by multivariate analysis in New Jersey, 1998-2007. ACE, angiotensin-converting enzyme; CL, confidence limits; EF, ejection fraction; HR, hazard ratio; LCL, lower confidence limit; UCL, upper confidence limit.
two decades, and the decrease was even more marked when adjusted for patient severity. 1 -5,8 In our study, despite a declining proportion of patients with EF ,35%, we did not observe such a decrease in either in-hospital or 2-year mortality. The expected decrease may have been obscured by the low mortality rates we observed. Previous studies have shown that pre-operative beta-blocker use decreased mortality or atrial fibrillation occurrence after surgery. 9, 17 These studies did not address the effect of betablockers on HF following CABG. We observed that pre-operative use of beta-blockers decreased the likelihood of admission for HF after surgery. However, despite the increasing number of patients with EF ,35% taking beta-blockers at the time of surgery and a more pronounced benefit in this group, there was an increasing trend of HF admissions. This may be attributed to suboptimal management of other risk factors that contribute to HF admission after CABG.
Although the benefit of ACE inhibition for patients with coronary artery disease is well established, 18, 19 there is not enough evidence to support the benefits of ACE inhibitors among CABG patients, either pre-operatively or early after CABG. 20, 21 Our study found no mortality benefit of ACE inhibitor use preoperatively. The apparent increased risk of HF admission after CABG with ACE inhibitor use maybe related to ACE inhibition as a marker of cardiac function. A source of bias in this database study is that the information is entered by different individuals at multiple sites. A limitation of this type of study is the lack of information on medication use after surgery. Also, a variety of surgical techniques, anaesthesia protocols, and surgical indications might have been utilized in the selection and management of the patients. The data pertain only to one state in the USA with a large and diverse population. Therefore, they may not be applicable to other populations with different characteristics under different practice patterns. Another limitation is that our definition of HF was based on the presence of ICD9 code 428; however, validation studies have reported high positive predictive values from 83.5% to 97% using both primary and secondary diagnosis in identifying HF. 22, 23 These studies also suggest that reliance on ICD9 codes may exclude a significant proportion of patients with clinical HF. Therefore, our study may underestimate the magnitude of the problem. Nevertheless, the large number of patients, the inclusion of all CABG patients in New Jersey, and the 10-year time span are factors that strengthen this study. In summary, from 1998 to 2007, CABG mortality in New Jersey remained unchanged. The EF was a strong predictor of mortality and HF admission up to 2 years after CABG. The use of betablockers pre-operatively significantly decreased the likelihood of HF admission after CABG, especially in patients with low EF (,35%). Despite the more pronounced benefit and increasing use of beta-blockers in patients with low EF, HF admission rates after CABG continued to rise. This may be related to CABG surgery being offered to an increasing number of patients with low EF. ACE inhibition pre-operatively brought no mortality benefit and increased the risk of HF admission, although this may just be a marker of cardiac function. Our study suggests that more effective and individualized management of potential factors leading to HF are necessary. A.E. Moreyra et al.
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